Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCK | P08631 | 5/20 | 0.58 |
| ▸ | BTK | Q06187 | 3/20 | 0.56 |
| ▸ | LCK | P06239 | 9/20 | 0.53 |
| ▸ | SRC | P12931 | 2/20 | 0.40 |
| ▸ | KDR | P35968 | 5/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | INSR | P06213 | 1/20 | 0.33 |
| ▸ | LYN | P07948 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27837094 | 0.74 | HCK (0.55) | HCKBTKLCKSRC | |
| SCHEMBL27817657 | 0.74 | HCK (0.55) | HCKBTKLCKSRCKDR | |
| SCHEMBL27837091 | 0.74 | HCK (0.55) | HCKBTKLCKSRCKDR | |
| SCHEMBL17470278 | 0.74 | HCK (1.00) | HCKBTKLCKSRCKDR | |
| SCHEMBL31205892 | 0.73 | KDR (0.39) | HCKLCKKDR | |
| SCHEMBL17470231 | 0.73 | HCK (1.00) | HCKBTKLCKSRCKDR | |
| SCHEMBL3240152 | 0.72 | LCK (0.56) | HCKLCKSRCKDRINSR | |
| SCHEMBL27817661 | 0.72 | HCK (0.52) | HCKBTKLCKSRC | |
| SCHEMBL17470232 | 0.71 | HCK (1.00) | HCKBTKLCKSRCKDR | |
| SCHEMBL17459087 | 0.71 | HCK (1.00) | HCKBTKLCKSRCKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12209076-B2 | Imidazolyl kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2025-01-28 | — | — | US | disclosed |
| US-20210147388-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-20210147388-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-05-20 | — | — | US | disclosed |
| US-10975058-B2 | Imidazolyl kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| US-10975058-B2 | Imidazolyl kinase inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3171874-B1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA FARBER CANCER INST INC (US) | 2020-11-18 | — | — | EP | disclosed |
| US-20200338087-A9 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20200338087-A9 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-29 | — | — | US | disclosed |
| US-20190367487-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-12-05 | — | — | US | disclosed |
| US-20190367487-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-12-05 | — | — | US | disclosed |
| US-20170224700-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170224700-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170224700-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20170204082-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204082-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| US-20170204082-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2017-07-20 | — | — | US | disclosed |
| EP-3177295-A2 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | Dana Farber Cancer Institute, Inc. (US) | 2017-06-14 | — | — | EP | disclosed |
| EP-3171874-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2017-05-31 | — | — | EP | disclosed |
| WO-2016023014-A2 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-02-11 | — | — | WO | disclosed |
| WO-2016014542-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2016-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190367487-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | PRKACB, PRKACG, PRKACA | HCK 280/4885BTK 396/4885LCK 181/4885 |
| US-20170204082-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | PRKACB, PRKACG, PRKACA | HCK 280/4885BTK 396/4885LCK 181/4885 |
| US-10975058-B2 | Imidazolyl kinase inhibitors and uses thereof | PRKACB, PRKACG, PRKACA | HCK 280/4885BTK 396/4885LCK 181/4885 |
| US-20170224700-A1 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK2, SIK3 | HCK 215/4885BTK 258/4885LCK 239/4885 |
| US-12209076-B2 | Imidazolyl kinase inhibitors and uses thereof | PRKACB, PRKACG, PRKACA | HCK 280/4885BTK 396/4885LCK 181/4885 |
| US-20210147388-A1 | IMIDAZOLYL KINASE INHIBITORS AND USES THEREOF | PRKACB, PRKACG, PRKACA | HCK 280/4885BTK 396/4885LCK 181/4885 |
| US-20200338087-A9 | USES OF SALT-INDUCIBLE KINASE (SIK) INHIBITORS | SIK1, SIK3, SIK2 | HCK 184/4885BTK 258/4885LCK 215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.